Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Cyclerion Therapeutics (CYCN) EBITDA Margin (2019 - 2025)

Historic EBITDA Margin for Cyclerion Therapeutics (CYCN) over the last 6 years, with Q3 2025 value amounting to 111.54%.

  • Cyclerion Therapeutics' EBITDA Margin rose 2611400.0% to 111.54% in Q3 2025 from the same period last year, while for Sep 2025 it was 126.2%, marking a year-over-year increase of 27191600.0%. This contributed to the annual value of 181.4% for FY2024, which is N/A changed from last year.
  • Cyclerion Therapeutics' EBITDA Margin amounted to 111.54% in Q3 2025, which was up 2611400.0% from 1797.85% recorded in Q2 2025.
  • Cyclerion Therapeutics' 5-year EBITDA Margin high stood at 27.8% for Q4 2024, and its period low was 21611.29% during Q1 2021.
  • Over the past 4 years, Cyclerion Therapeutics' median EBITDA Margin value was 1798.77% (recorded in 2025), while the average stood at 3486.65%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -196166200bps in 2021, then surged by 197859700bps in 2022.
  • Over the past 4 years, Cyclerion Therapeutics' EBITDA Margin (Quarter) stood at 2690.06% in 2021, then tumbled by -63bps to 4389.87% in 2022, then skyrocketed by 101bps to 27.8% in 2024, then plummeted by -501bps to 111.54% in 2025.
  • Its last three reported values are 111.54% in Q3 2025, 1797.85% for Q2 2025, and 1798.77% during Q1 2025.